Cytokeratin 5 positive cells represent a steroid receptor negative and therapy resistant subpopulation in luminal breast cancers

Breast Cancer Research and Treatment

Volumn 128, Issue 1, 2011, Pages 45-55

  Kabos, Peter ^a   Haughian, James M ^a   Wang, Xinshuo ^a   Dye, Wendy W ^a   Finlayson, Christina ^b   Elias, Anthony ^a   Horwitz, Kathryn B ^a   Sartorius, Carol A ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

Breast cancer; Cytokeratin 5; Endocrine therapy; Estrogen receptors; Tamoxifen; Tumor initiating cells

Indexed keywords

CYTOKERATIN 5; DOCETAXEL; ESTRADIOL; ESTROGEN RECEPTOR; EXEMESTANE; FLUOROURACIL; FULVESTRANT; PROGESTERONE RECEPTOR; TAMOXIFEN;

ADJUVANT THERAPY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CELL PROLIFERATION; CONTROLLED STUDY; DRUG SENSITIVITY; ENRICHMENT CULTURE; FEMALE; GENE EXPRESSION; HORMONAL THERAPY; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS, HORMONAL; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KERATIN-5; NEOADJUVANT THERAPY; PHENOTYPE; RECEPTORS, PROGESTERONE; TAMOXIFEN;

EID: 79959213451     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-010-1078-6     Document Type: Article

References (38)

1. X Cui R Schiff G Arpino, et al. 2005 Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy J Clin Oncol 23 7721 7735 10.1200/JCO.2005.09.004 16234531 10.1200/JCO.2005.09.004 1:CAS:528:DC%2BD2MXht1WrsrrM (Pubitemid 46291836)
2. CM Perou T Sorlie MB Eisen, et al. 2000 Molecular portraits of human breast tumours Nature 406 747 752 10.1038/35021093 10963602 10.1038/35021093 1:CAS:528:DC%2BD3cXmt1CnsLw%3D
3. S Paik G Tang S Shak, et al. 2006 Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer J Clin Oncol 24 3726 3734 10.1200/JCO.2005.04.7985 16720680 10.1200/JCO.2005.04.7985 1:CAS:528:DC%2BD28XpsVaqsrs%3D (Pubitemid 46622311)
4. CK Osborne R Schiff 2005 Estrogen-receptor biology: continuing progress and therapeutic implications J Clin Oncol 23 1616 1622 15755967 10.1200/JCO.2005.10.036 1:CAS:528:DC%2BD2MXjtVCqur0%3D (Pubitemid 46211414)
5. M Dean T Fojo S Bates 2005 Tumour stem cells and drug resistance Nat Rev Cancer 5 275 284 10.1038/nrc1590 15803154 10.1038/nrc1590 1:CAS:528: DC%2BD2MXivVarsL4%3D (Pubitemid 40488633)
6. M Diehn RW Cho NA Lobo, et al. 2009 Association of reactive oxygen species levels and radioresistance in cancer stem cells Nature 458 780 783 10.1038/nature07733 19194462 10.1038/nature07733 1:CAS:528:DC%2BD1MXhsVCrtbc%3D
7. M Al-Hajj MS Wicha A Benito-Hernandez, et al. 2003 Prospective identification of tumorigenic breast cancer cells Proc Natl Acad Sci USA 100 3983 3988 10.1073/pnas.0530291100 12629218 10.1073/pnas.0530291100 1:CAS:528:DC%2BD3sXivFSqtbs%3D (Pubitemid 36418143)
8. CM Fillmore C Kuperwasser 2008 Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy Breast Cancer Res 10 R25 10.1186/bcr1982 18366788 10.1186/bcr1982
9. X Li MT Lewis J Huang, et al. 2008 Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy J Natl Cancer Inst 100 672 679 10.1093/jnci/djn123 18445819 10.1093/jnci/djn123 1:CAS:528:DC%2BD1cXlslymtbg%3D
10. TM Phillips WH McBride F Pajonk 2006 The response of cd24(-/low)/cd44+ breast cancer-initiating cells to radiation J Natl Cancer Inst 98 1777 1785 17179479 10.1093/jnci/djj495 (Pubitemid 46017929)
11. R Liu X Wang GY Chen, et al. 2007 The prognostic role of a gene signature from tumorigenic breast-cancer cells N Engl J Med 356 217 226 10.1056/NEJMoa063994 17229949 10.1056/NEJMoa063994 1:CAS:528: DC%2BD2sXns12mug%3D%3D (Pubitemid 46143225)
12. M Shipitsin LL Campbell P Argani, et al. 2007 Molecular definition of breast tumor heterogeneity Cancer Cell 11 259 273 10.1016/j.ccr.2007.01.013 17349583 10.1016/j.ccr.2007.01.013 1:CAS:528:DC%2BD2sXjsVymtL0%3D (Pubitemid 46349843)
13. BK Abraham P Fritz M McClellan, et al. 2005 Prevalence of cd44+/cd24-/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis Clin Cancer Res 11 1154 1159 15709183 1:CAS:528:DC%2BD2MXht1ynt7k%3D (Pubitemid 40175765)
14. G Honeth PO Bendahl M Ringner, et al. 2008 The cd44+/cd24- phenotype is enriched in basal-like breast tumors Breast Cancer Res 10 R53 10.1186/bcr2108 18559090 10.1186/bcr2108
15. C Ginestier MH Hur E Charafe-Jauffret, et al. 2007 Aldh1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome Cell Stem Cell 1 555 567 10.1016/j.stem.2007.08.014 18371393 10.1016/j.stem.2007.08.014 1:CAS:528:DC%2BD2sXhsVahtrvF (Pubitemid 350056407)
16. E Charafe-Jauffret C Ginestier F Iovino, et al. 2009 Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature Cancer Res 69 1302 1313 10.1158/0008-5472.CAN-08- 2741 19190339 10.1158/0008-5472.CAN-08-2741 1:CAS:528:DC%2BD1MXhslynsrw%3D
17. CS O'Brien SJ Howell G Farnie, et al. 2009 Resistance to endocrine therapy: are breast cancer stem cells the culprits? J Mammary Gland Biol Neoplasia 14 45 54 10.1007/s10911-009-9115-y 19252972 10.1007/s10911-009-9115-y
18. KB Horwitz WW Dye JC Harrell, et al. 2008 Rare steroid receptor-negative basal-like tumorigenic cells in luminal subtype human breast cancer xenografts Proc Natl Acad Sci USA 105 5774 5779 10.1073/pnas.0706216105 18391223 10.1073/pnas.0706216105 1:CAS:528:DC%2BD1cXltFShsb4%3D (Pubitemid 351758448)
19. E Lim F Vaillant D Wu, et al. 2009 Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers Nat Med 15 907 913 10.1038/nm.2000 19648928 10.1038/nm.2000 1:CAS:528:DC%2BD1MXpt1Onsro%3D
20. W Boecker H Buerger 2003 Evidence of progenitor cells of glandular and myoepithelial cell lineages in the human adult female breast epithelium: a new progenitor (adult stem) cell concept Cell Prolif 36 Suppl 1 73 84 14521517 10.1046/j.1365-2184.36.s.1.7.x (Pubitemid 37521845)
21. W Boecker R Moll C Poremba, et al. 2002 Common adult stem cells in the human breast give rise to glandular and myoepithelial cell lineages: a new cell biological concept Lab Investig 82 737 746 0.1002/path.1241
22. I Keydar L Chen S Karby, et al. 1979 Establishment and characterization of a cell line of human breast carcinoma origin Eur J Cancer 15 659 670 228940 1:CAS:528:DyaE1MXkslartL4%3D (Pubitemid 9198534)
23. CA Sartorius DM Harvell T Shen, et al. 2005 Progestins initiate a luminal to myoepithelial switch in estrogen-dependent human breast tumors without altering growth Cancer Res 65 9779 9788 10.1158/0008-5472.CAN-05-0505 16266999 10.1158/0008-5472.CAN-05-0505 1:CAS:528:DC%2BD2MXhtFKktL%2FK (Pubitemid 41541455)
24. DM Harvell NS Spoelstra M Singh, et al. 2008 Molecular signatures of neoadjuvant endocrine therapy for breast cancer: characteristics of response or intrinsic resistance Breast Cancer Res Treat 112 475 488 10.1007/s10549-008- 9897-4 18327671 10.1007/s10549-008-9897-4 1:CAS:528:DC%2BD1cXhtl2mu7bN
25. MC Cheang D Voduc C Bajdik, et al. 2008 Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype Clin Cancer Res 14 1368 1376 10.1158/1078-0432.CCR-07-1658 18316557 10.1158/1078-0432.CCR-07-1658 1:CAS:528:DC%2BD1cXislSrs7o%3D (Pubitemid 351413917)
26. J Hugh J Hanson MC Cheang, et al. 2009 Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the bcirg 001 trial J Clin Oncol 27 1168 1176 10.1200/JCO.2008.18.1024 19204205 10.1200/JCO.2008.18.1024 1:CAS:528: DC%2BD1MXktFKhs7Y%3D
27. DM Abd El-Rehim SE Pinder CE Paish, et al. 2004 Expression of luminal and basal cytokeratins in human breast carcinoma J Pathol 203 661 671 10.1002/path.1559 15141381 10.1002/path.1559 (Pubitemid 38714103)
28. K Malzahn M Mitze M Thoenes, et al. 1998 Biological and prognostic significance of stratified epithelial cytokeratins in infiltrating ductal breast carcinomas Virchows Arch 433 119 129 9737789 10.1007/s004280050226 1:CAS:528:DyaK1cXkslyrtLY%3D (Pubitemid 28401168)
29. M van de Rijn CM Perou R Tibshirani, et al. 2002 Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome Am J Pathol 161 1991 1996 12466114 10.1016/S0002-9440(10)64476-8 (Pubitemid 35434844)
30. T Kuukasjarvi J Kononen H Helin, et al. 1996 Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy J Clin Oncol 14 2584 2589 8823339 1:CAS:528:DyaK28XlvVGisL0%3D (Pubitemid 26300127)
31. V Spataro K Price A Goldhirsch, et al. 1992 Sequential estrogen receptor determinations from primary breast cancer and at relapse: prognostic and therapeutic relevance. The international breast cancer study group (formerly Ludwig group) Ann Oncol 3 733 740 1450062 1:STN:280:DyaK3s%2FotFemsg%3D%3D
32. CJ Creighton X Li M Landis, et al. 2009 Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features Proc Natl Acad Sci USA 106 13820 13825 10.1073/pnas.0905718106 19666588 10.1073/pnas.0905718106 1:CAS:528:DC%2BD1MXhtFWksLjF
33. CJ Creighton S Massarweh S Huang, et al. 2008 Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts Cancer Res 68 7493 7501 10.1158/0008-5472. CAN-08-1404 18794137 10.1158/0008-5472.CAN-08-1404 1:CAS:528:DC%2BD1cXhtFWltb7F
34. S Massarweh CK Osborne CJ Creighton, et al. 2008 Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function Cancer Res 68 826 833 10.1158/0008-5472.CAN-07-2707 18245484 10.1158/0008-5472.CAN-07-2707 1:CAS:528:DC%2BD1cXhtlygtrY%3D (Pubitemid 351206760)
35. RB Clarke A Howell CS Potten, et al. 1997 Dissociation between steroid receptor expression and cell proliferation in the human breast Cancer Res 57 4987 4991 9371488 1:CAS:528:DyaK2sXnsV2ktrY%3D (Pubitemid 27498105)
36. C Liedtke K Broglio S Moulder, et al. 2009 Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer Ann Oncol 20 1953 1958 10.1093/annonc/mdp263 19596702 10.1093/annonc/mdp263 1:STN:280:DC%2BD1MjntFOrtQ%3D%3D
37. V Guarneri S Giovannelli G Ficarra, et al. 2008 Comparison of her-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management Oncologist 13 838 844 10.1634/theoncologist.2008-0048 18650259 10.1634/theoncologist.2008-0048 1:CAS:528:DC%2BD1cXhtF2qs7vP
38. PB Gupta TT Onder G Jiang, et al. 2009 Identification of selective inhibitors of cancer stem cells by high-throughput screening Cell 138 645 659 10.1016/j.cell.2009.06.034 19682730 10.1016/j.cell.2009.06.034 1:CAS:528:DC%2BD1MXhsVCjs73E